Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: mineralocorticoid receptor antagonist Clear all
Recruiting Phase 4 Interventional

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

NCT05030545
View directory record Official record
Conditions
Primary Aldosteronism, Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 3, 2026, 10:49 PM EDT
Withdrawn Not applicable Interventional

Email Nudges to Improve GDMT (MRA) Adherence in Heart Failure

NCT05806970
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Email Nudge
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Results available

Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity

NCT04519164
View directory record Official record
Conditions
Metabolic Syndrome, Hypertension, Overweight and Obesity
Interventions
Eplerenone, Chlorthalidone with potassium chloride
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment

NCT02653014
View directory record Official record
Conditions
Healthy, Renal Insufficiency
Interventions
KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Evergreen Park, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

Heart Failure Polypill at a Safety Net Hospital

NCT06029712
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, HIV Infections
Interventions
Heart failure polypill, Control Rx
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 3, 2026, 10:49 PM EDT
Withdrawn Phase 4 Interventional

CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression

NCT01275352
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 3, 2026, 10:49 PM EDT
Not listed No phase listed Observational

Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

NCT06201000
View directory record Official record
Conditions
Genetic Polymorphisms, Heart Failure
Interventions
SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
Drug
Lead sponsor
October 6 University
Other
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 3, 2026, 10:49 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction

NCT05806138
View directory record Official record
Conditions
Breast Cancer, Cardiac Dysfunction
Interventions
Vericiguat, Optimal medical therapy
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Not applicable Interventional Results available

Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)

NCT02740179
View directory record Official record
Conditions
HIV
Interventions
Eplerenone, Placebo, Lifestyle Modification
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Not applicable Interventional Results available

Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure (BETTER CARE-HF)

NCT05275920
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions
Best Practice Alert (BPA), In-Basket Message
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
2,211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY2623091 in Participants With High Blood Pressure

NCT02194465
View directory record Official record
Conditions
Primary Hypertension
Interventions
LY2623091, Tadalafil, Spironolactone, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
33
States / cities
Glendale, Arizona • Concord, California • Encinitas, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Not applicable Interventional

Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study

NCT02167464
View directory record Official record
Conditions
Hypertension
Interventions
Renin treatment-guided Therapeutics, Referral Hypertension specialist, Aldosterone Antagonist
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Anderson, South Carolina • Beaufort, South Carolina • Florence, South Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 3, 2026, 10:49 PM EDT
Completed No phase listed Observational

Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas

NCT02362308
View directory record Official record
Conditions
Primary Aldosteronism
Interventions
Adrenalectomy, mineralocorticoid receptor antagonist
Other · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 3, 2026, 10:49 PM EDT
Completed No phase listed Observational

Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure

NCT05077293
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions
Best Practice Alert (BPA), In-Basket Message
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function

NCT00094302
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Heart Failure, Congestive
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Carelon Research
Other
Eligibility
50 Years and older
Enrollment
3,445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN

NCT03683069
View directory record Official record
Conditions
Hypertension, Genetics Hypertension
Interventions
Eplerenone vs Amlodipine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease

NCT02837237
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 3, 2026, 10:49 PM EDT
Terminated Phase 2 Interventional Results available

Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency

NCT04588688
View directory record Official record
Conditions
Central Adrenal Insufficiency, Mifepristone
Interventions
Mifepristone
Drug
Lead sponsor
Tobias Else
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance

NCT02585843
View directory record Official record
Conditions
Heart Failure
Interventions
Spironolactone 100mg, Spironolactone 25mg
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 3, 2026, 10:49 PM EDT
Active, not recruiting No phase listed Observational

Rubix LS Diabetic Kidney Disease (DKD) Registry Study

NCT07348718
View directory record Official record
Conditions
Diabetic Kidney Disease (DKD)
Interventions
Kidney-Protective Therapies Used in Routine Care
Drug
Lead sponsor
Rubix LS
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 3, 2026, 10:49 PM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 3, 2026, 10:49 PM EDT
Terminated Not applicable Interventional Results available

HF Assessment With BNP in the Home: Part II

NCT02351063
View directory record Official record
Conditions
Heart Failure
Interventions
Changes of heart failure medications
Drug
Lead sponsor
Alere San Diego
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Loma Linda, California • San Diego, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 3, 2026, 10:49 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

NCT04300881
View directory record Official record
Conditions
Vitreomacular Traction, Subretinal Edema
Interventions
Eplerenone
Drug
Lead sponsor
Wagner Macula & Retina Center
Other
Eligibility
19 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Informational Nudge to Improve Heart Failure Prescribing

NCT05986695
View directory record Official record
Conditions
Heart Failure
Interventions
Alert, Peer comparison report
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 3, 2026, 10:49 PM EDT